Tyrosine kinases: a target of epigenetic influences and a new direction in the treatment of multiple sclerosis

Abstract

Studies have shown that tyrosine kinases can be important in the pathogenesis of multiple sclerosis (MS) through the regulatory network of microRNAs. A microRNA network-based analysis revealed 17 receptor pathways activated by tyrosine kinase and regulated by microRNAs encoded at the DLK1-DIO3 locus on chromosome 14. Tyrosine kinases are actively involved in the epigenetic regulation of the pathological process in MS with the participation of a microRNA network and thus attract attention as a target for the development of new ways for the treatment of MS. The greatest attention was attracted by Bruton tyrosine kinase inhibitors (TKBi), which showed their ability to suppress the activity of autoimmune inflammatory lesions in the MS model - experimental autoimmune encephalomyelitis (EAE). This is due to the influence of TRB on the activity of B cells, which have a critical role in the development of the pathological process. The review discusses the types of TRBi, the features of their action in EAE and the results of the first studies in MS.